国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (12): 918-920.doi: 10.3760/cma.j.issn.1673422X.2016.12.009

• 综述 • 上一篇    下一篇

 肿瘤的精准免疫治疗

张百红, 岳红云   

  1. 兰州军区兰州总医院肿瘤科
  • 出版日期:2016-12-08 发布日期:2016-11-02
  • 基金资助:

    甘肃省自然科学基金（1308RJZA181）

Precision immunotherapy for cancer

ZHANG  Bai-Hong, YUE  Hong-Yun   

  1. Department of Oncology, Lanzhou General Hospital of Lanzhou Military Region, Lanzhou 730050, China
  • Online:2016-12-08 Published:2016-11-02
  • Supported by:

    Natural Science Foundation of Gansu Province of China (1308RJZA181)

PDF

1587

摘要： 免疫检查点抑制剂和基因编辑T细胞通过靶向T细胞的调节通路增强抗肿瘤免疫，现已成为精准免疫治疗肿瘤的新武器。但免疫检查点抑制剂持续诱导免疫反应仅对少部分患者有效，而应用嵌合抗原受体或T细胞受体重新修饰T细胞的方法因缺乏肿瘤特异性抗原而受到限制。联合治疗模式和筛选优势人群是未来免疫检查点抑制剂发展的主要方向，设计双抗体或特异性抗体的T细胞可能提高精准免疫治疗的效果。

关键词: 肿瘤, 精准免疫学, 免疫检查点抑制剂

Abstract: Immune checkpoint blockades and modified T cells, which target regulating pathways in T cells to enhance antitumor immune response, provide a new weapon for cancer precision immunotherapy. However, immune checkpoint blockades result in longlasting responses only in a fraction of patients, while T cells newly modified by chimeric antigen receptors or T cell receptors are constrained by the rarity of tumorspecific antigens. Combination of therapy model and identification of advantage patients represent a path forward for immune checkpoint blockades in cancer therapy. Dualreceptor or specific receptor also opens the door to improve immune responses for precision immunotherapy.

Key words: Neoplasms, Precision immunology, Immune checkpoint blockades